Concepedia

Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis

Elizabeth Baker, William T. Harris, Steven M. Rowe, Sarah B. Rutland, Gabriela R. Oates

Journal of Cystic Fibrosis · 2020 · 34 citations · 30 references

DOIFull text

Open access

Concepts

References

30

The Health consequences of smoking—50 years of progress : a report of the Surgeon General

Boris D. Lushniak, Jonathan M. Samet, Terry F. Pechacek et al. · 2014 · 5K citations

, , +12

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>

Claire Wainwright, J.S. Elborn, Bonnie W. Ramsey et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

, , +15

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Fredrick Van Goor, Sabine Hadidaꝉ, Peter D. J. Grootenhuis et al. · Proceedings of the National Academy of Sciences · 2011 · 1.1K citations · Full text

, , +13

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

Jennifer L. Taylor‐Cousar, À. Munck, Edward F. McKone et al. · New England Journal of Medicine · 2017 · 778 citations · Full text

, , +10

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

Steven M. Rowe, Cori Daines, Felix C. Ringshausen et al. · New England Journal of Medicine · 2017 · 511 citations · Full text

, , +13